Screener
Bioventus BVS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Inventories | 316 | (4,690) |
| Accounts payable and accrued expenses | (11,548) | (22,681) |
| Other current and noncurrent assets and liabilities | 1,512 | 1,272 |
| Net cash from operating activities | 28,807 | 6,607 |
| Investing activities: | ||
| Settlement from the sale of a business | — | (686) |
| Purchase of property and equipment | (1,534) | (1,509) |
| Purchase of equity securities | (1,500) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's operating cash flow?
- Bioventus (BVS) reported operating cash flow of $19.87M in Q2 2026.
- How has Bioventus's operating cash flow changed year-over-year?
- Bioventus's operating cash flow decreased by 23.4% year-over-year, from $25.94M to $19.87M.
- What is the long-term trend for Bioventus's operating cash flow?
- Over 2 years (2021 to 2025), Bioventus's operating cash flow has grown at a 80.2% compound annual growth rate (CAGR), from $22.99M to $74.67M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Bioventus's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude